Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).
about
Attenuated osteoarticular phenotype of type VI mucopolysaccharidosis: a report of four patients and a review of the literatureTherapies for the bone in mucopolysaccharidosesCNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)Bioinformatic Analysis of the Human Recombinant Iduronate 2-Sulfate Sulfatase.Respiratory and sleep disorders in mucopolysaccharidosisThe factors affecting lipid profile in adult patients with MucopolysaccharidosisImpact of Enzyme Replacement Therapy and Hematopoietic Stem Cell Therapy on Growth in Patients with Hunter Syndrome.[Efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II with and without comparison to placebo: systematic review and meta-analysis].Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and managementA study of the relationship between clinical phenotypes and plasma iduronate-2-sulfatase enzyme activities in Hunter syndrome patients.Comparative study of idursulfase beta and idursulfase in vitro and in vivo.Plasmatic and Urinary Glycosaminoglycans Characterization in Mucopolysaccharidosis II Patient Treated with Enzyme-Replacement Therapy with Idursulfase.Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients.Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI.Mucopolysaccharidosis Type II and the G374sp Mutation.Template synthesis of test tube nanoparticles using non-destructive replicationCauses of death and clinical characteristics of 34 patients with Mucopolysaccharidosis II in Taiwan from 1995-2012.Topical enzyme-replacement therapy restores transglutaminase 1 activity and corrects architecture of transglutaminase-1-deficient skin grafts.Pilot study of the safety and effect of adalimumab on pain, physical function, and musculoskeletal disease in mucopolysaccharidosis types I and IITherapy for the mucopolysaccharidoses.Enzymes approved for human therapy: indications, mechanisms and adverse effects.Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II.Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review.Cardiac issues in adults with the mucopolysaccharidoses: current knowledge and emerging needs.Relationship of sleep to pulmonary function in mucopolysaccharidosis II.Successful noninvasive ventilation and enzyme replacement therapy in an adult patient with morbus hunterThree Adult Siblings with Mucopolysaccharidosis Type II (Hunter Syndrome): A Report on Clinical Heterogeneity and 12 Months of Therapy with Idursulfase.Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.Plasmatic kinetics of dermatan sulfate during enzyme replacement therapy with iduronate-2-sulfatase in a mucopolysaccharidosis II patient.Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey.Mucopolysaccharidosis VI: cardiac involvement and the impact of enzyme replacement therapy.Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II.A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II.Identification of 11 novel mutations in 49 Korean patients with mucopolysaccharidosis type II.Improvement of CNS defects via continuous intrathecal enzyme replacement by osmotic pump in mucopolysaccharidosis type II mice.Drugs obtained by biotechnology processing
P2860
Q26830003-B50A07EF-CC4C-4C68-8B37-7C25C8EB2060Q26852308-4551984D-9456-4CB7-B1C5-EE97A594E14AQ27333793-9A08FC99-897B-4875-A6E5-72C49DFE504FQ30389692-10D7C0DD-880A-4161-A5A7-362B65FC1254Q30457547-CD63F8BE-4A77-4899-B766-54BF8B050654Q33716134-083D656F-241C-44E2-91CA-D252C50163D3Q33923815-A0E8BFF5-C7AD-4F30-B76B-C7B8815BE491Q35427537-4D7CF96D-6E5B-4382-B0F3-5F7B97334D45Q35571515-E9A8FF64-E558-42C8-A277-44458B4398AFQ35587435-4C2B4203-BD1B-4F79-89F1-0C245F35071BQ35861337-C1899CF8-F72C-464F-81FB-88F2EDE68C28Q36188048-94888C08-36D2-4107-9B0C-4F945A1DA17EQ36433407-45BE0F91-C41E-42E7-979C-F75D15119F37Q36571573-7C2C06D6-6BEE-4F5F-BD8C-F23E6D026D37Q36662835-162D12E4-771C-49A4-B9E1-5EF858893424Q36883369-21078989-D278-4E0C-838F-EB56720A81B8Q36946769-D603BAC4-4668-41A6-AED6-ED41B7A6A3E1Q37045386-31FEE651-A475-470E-9920-477D474FC866Q37217029-6002DAB8-33B7-4D11-B8DB-CA66AF4D674AQ37587862-F506897F-330D-4220-B68E-6E52E312FE91Q37972592-ECA7DCB3-D5FF-4763-943A-9491B01D85EBQ38342838-35DD93FF-5411-4D76-B733-A786D7426D28Q38634722-8A799550-1CB2-442B-BBEF-D11A2370191DQ38695475-C1BEB13C-A21E-4144-AA7D-EC52A4AB43E0Q38714026-CAFE46BD-FF89-4E56-9C4E-E46099C9A81AQ38814371-9C63E673-D2A9-4CAF-B47C-193132C91EAAQ41109827-61F8EC12-896A-4788-8E06-718A1B3CE5BCQ41934288-2047FF04-D534-4598-9BAA-61BA068BA0F0Q42130903-D2E980EA-37FA-4824-ADA3-FE89E91D75E3Q42281140-B0BF269E-755D-4D38-A410-CE6D9B26E0B9Q43530570-80BDE14B-D2FB-427C-98C8-01461A93A9A7Q44749231-BEA01954-931F-44D8-85FD-B543AC77993BQ46150910-7B9B1389-2582-4D3A-99DD-304D940EF823Q46739999-4570128E-B85B-423F-BC15-60AA1422335AQ47573614-59CEBE7D-E175-43B3-A912-B6D891A37746Q52722420-5EB56118-DF5F-41DC-8BA7-70138A4C0445Q53439750-7E33A5CA-24AC-4DF5-9F9A-89F4D87FEA8EQ54202070-05D1ABD4-5AC6-4E62-BFC7-B89A03D80DE0Q56456855-5C784A88-7B33-4E95-A673-2853DA25BFDF
P2860
Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Japan Elaprase Treatment (JET) ...... polysaccharidosis II, MPS II).
@ast
Japan Elaprase Treatment (JET) ...... polysaccharidosis II, MPS II).
@en
type
label
Japan Elaprase Treatment (JET) ...... polysaccharidosis II, MPS II).
@ast
Japan Elaprase Treatment (JET) ...... polysaccharidosis II, MPS II).
@en
prefLabel
Japan Elaprase Treatment (JET) ...... polysaccharidosis II, MPS II).
@ast
Japan Elaprase Treatment (JET) ...... polysaccharidosis II, MPS II).
@en
P2093
P1476
Japan Elaprase Treatment (JET) ...... polysaccharidosis II, MPS II).
@en
P2093
Akemi Tanaka
Gerald F Cox
Hiroyuki Ida
Tadao Orii
Toju Tanaka
Torayuki Okuyama
Yasuyuki Suzuki
Yoshikatsu Eto
P356
10.1016/J.YMGME.2009.08.006
P577
2010-01-01T00:00:00Z